Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of June 30, 2022
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission, Commission File Number 001-39446. It states that the report is furnished for the sole purposes of providing Exhibit 99.1, unaudited interim condensed consolidated financial statements as of June 30, 2022 and for the six month periods ended June 30, 2022 and 2021, and Exhibit 99.2, Management's Discussion and Analysis of Financial Condition and Results of Operations. The information is incorporated by reference into Form F-3, File No. 333-259613. The report is signed August 18, 2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 6-K — CureVac N.V.: Interim Condensed Consolidated Financial Statements as of June 30, 2022.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2022-08-18-0001410578-22-002669-40750062c2/
, SHA-256 6b274e85a9568d435333f7cc45ce73590d6f88f94b1dc414dd10827ed60cec53.Full text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of August 2022
Commission File Number: 001-39446
CureVac N.V.
( Exact Name of Registrant as Specified in Its Charter )
Friedrich-Miescher-Strasse 15, 72076
Tübingen, Germany
+49 7071 9883 0
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F | ⌧ | Form 40-F | ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes | ☐ | No | ⌧
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes | ☐ | No | ⌧
This Report of Foreign Private Issuer on Form 6-K (this "Form 6-K") is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the "SEC") for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac's financial results and business updates as of June 30, 2022 and for the six month periods ended June 30, 2022 and 2021; (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management's Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of June 30, 2022 and for the six month periods ended June 30, 2022 and 2021;
The information included in this Form 6-K (including Exhibits 99.1 and 99.2) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CUREVAC N.V.
By: | /s/ Franz-Werner Haas, LLD, LLM
Chief Executive Officer
Date: August 18, 2022
EXHIBIT INDEX
EXHIBIT NO. | DESCRIPTION
99.1 | Unaudited Interim Condensed Consolidated Financial Statements As of June 30, 2022 and for the six months ended June 30, 2022 and 2021
99.2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations
File and source
- File
- SEC_CVAC_6-K_filed2022-08-18_0001410578-22-002669.htm
- Size
- 117,815 bytes
- SHA-256
- 6b274e85a9568d435333f7cc45ce73590d6f88f94b1dc414dd10827ed60cec53
- Original
- www.sec.gov